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Abstract 
Infection with hepatitis E virus (HEV) of genotype 3 may result in chronic hepatitis in 
immunocompromised patients. Reduction of immunosuppression or treatment with ribavirin or 
pegylated interferon-α can result in viral clearance. However, safer and more effective 
treatment options are needed. Here, we demonstrate that sofosbuvir inhibits the replication of 
HEV genotype 3 both in subgenomic replicon systems as well as a full-length infectious clone. 
Moreover, the combination of sofosbuvir and ribavirin results in an additive antiviral effect. 
Sofosbuvir may be considered as an add-on therapy to ribavirin for the treatment of chronic 
hepatitis E in immunocompromised patients. 
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Hepatitis E virus (HEV) is believed to be the most common cause of acute hepatitis and 
jaundice in the world [1-3]. While HEV genotypes (gt) 1 and 2 infect only humans, gt 3 and 4 
are zoonotic viruses that also infect swine and other animal species. Acute hepatitis E is 
usually self-limited. However, HEV of gt 3 can persist in immunocompromised patients, 
especially organ transplant recipients, causing chronic hepatitis, which may progress to 
cirrhosis and liver graft failure [1-4]. Reduction of immunosuppressive therapy, ribavirin (RBV) 
or pegylated interferon-α have been used with varying success, allowing for viral clearance in 
up to 78% of patients [1-6]. However, failure of RBV has been described [7]. Hence, safer and 
more effective treatment options are needed. 
A luciferase encoding subgenomic replicon construct derived from the HEV gt 3 Kernow-C1 
p6 strain (both kindly provided by Suzanne U. Emerson, NIH, Bethesda, MD) was used to 
develop a selectable subgenomic replicon in which part of open reading frame 2 (ORF2) and 
ORF3 was replaced by a neomycin phosphotransferase gene (Fig. 1A) (Suppl. Material and 
Methods). Transfection of in vitro-transcribed replicon RNA into the Huh-7 human 
hepatocellular carcinoma-derived cell line S10-3 (kindly provided by Suzanne U. Emerson) 
allowed the establishment of a cell line harboring autonomously replicating HEV RNA, 
designated as HEV3 Rep/Neo. The full-length and subgenomic HEV RNA species were 
detectable in this cell line by Northern blot (Fig. 1B). Steady-state HEV RNA replication was 
quantified by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) (Suppl. 
Material and Methods). 
In line with data previously obtained in a transient HEV Kernow-C1 replicon assay [8], 
treatment of HEV3 Rep/Neo cells with interferon-α (IFN-α) or RBV for 48 h led to a dose-
dependent decrease of HEV RNA levels relative to untreated cells, with 50% inhibitory 
concentrations (IC50) of 8.5 IU/ml and 8 µM, respectively, without affecting cell viability (Fig. 
1C; Suppl. Material and Methods). 
We observed that sofosbuvir (SOF), the oral prodrug of a nucleotide hepatitis C virus (HCV) 
RNA-dependent RNA polymerase inhibitor [9], efficiently inhibited HEV RNA replication in 
HEV3 Rep/Neo cells (IC50 1.2 µM; Fig. 1C). This antiviral activity was confirmed in a transient 
gt 3 reporter replicon system while a gt 1 replicon proved to be less sensitive to inhibition by 
SOF in this assay (Suppl. Fig. 1A). In addition, two closely related nucleoside analogs with 
known inhibitory activity on HCV replication, i.e. 2'-C-methyladenosine and 2'-C-methylcytidine 
[10], inhibited HEV RNA replication (IC50 3.5 µM and 22 µM, respectively; data not shown). By 
contrast, the non-nucleoside HCV polymerase inhibitor nesbuvir [11] as well as the 
HIV/hepatitis B virus reverse transcriptase/DNA polymerase inhibitors lamivudine and 
tenofovir did, as expected, not show any effect on HEV replication (Fig. 1C and Suppl. Fig. 2). 
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Next, the inhibitory potential of SOF was investigated in the full-length infectious p6 clone [12]. 
To this end, S10-3 cells were transfected with in vitro-transcribed full-length HEV p6 RNA. As 
the peak of HEV replication is reached 6 d post-transfection [12], inhibitors were added at day 
4 post-transfection after which cultures were further incubated for 48 h. Total RNA and protein 
were analyzed by RT-qPCR and immunoblot, respectively. In agreement with the results 
obtained in the subgenomic replicon system, IFN-α, RBV and SOF, but not nesbuvir, markedly 
decreased both HEV RNA levels (Fig. 1D) and the expression of ORF2 protein (Fig. 1E). 
Next, we assessed the antiviral effect of combinations of different concentrations of SOF and 
RBV in HEV3 Rep/Neo cells as well as in human induced pluripotent stem cell-derived 
hepatocyte-like cells (iHeps) [13, 14] infected with HEV of gt 3 (Suppl. Material and Methods). 
The addition of RBV allowed for a maximal inhibition of HEV RNA replication at lower 
concentrations of SOF in both systems (Fig. 2A and C). We demonstrated earlier that the 
combination of RBV and 2’-C-methylcytidine results in an antagonistic effect on HCV 
replication, which is explained by the fact that RBV results in increased intracellular CTP pools 
which compete with 2'-C-methylcytidine 5'-triphosphate at the polymerase level [15]. However, 
the combined effect of RBV and SOF on HEV replication was found to be additive in Huh-7-
derived replicon cells and in HEV-infected iHeps (Fig. 2B and D). This additive effect was 
confirmed in the transient replication assay (Suppl. Fig. 3). 
In conclusion, using both selectable and transient subgenomic HEV replicons, an infectious 
cell culture system, and two different cellular systems, we demonstrate that SOF, an approved 
drug that is successfully used in the treatment of HCV infection, inhibits HEV gt 3 replication 
in vitro and results in an additive effect when combined with RBV. The anti-HEV activity of 
SOF is markedly less pronounced than the anti-HCV activity of the compound (IC50 ranging 
from 0.014 to 0.11 µM depending on replicon genotype) [16]. However, the concentrations of 
SOF reached in the liver may be sufficiently high to contribute, together with RBV, to inhibition 
of HEV replication. Given the additive in vitro antiviral effect of both drugs, a combination of 
the two may result in a faster and more efficient inhibition of HEV replication in 
immunocompromised patients with chronic hepatitis E as compared to RBV monotherapy. 
 
Acknowledgements 
We gratefully acknowledge Suzanne U. Emerson for sharing reagents. 
5 
Legends to Figures 
 
Figure 1. Inhibition of HEV RNA replication in a selectable subgenomic replicon system 
and an infectious clone. (A) Schematic representation of the HEV genome and the selectable 
subgenomic replicon (Suppl. Materials and Methods). 7mG, 7-methylguanosine. (B) Northern 
blot analysis of HEV3 Rep/Neo cells. Total RNA was extracted from parental S10-3 cells (-) or 
HEV3 Rep/Neo cells (+) and analyzed by Northern blot using 32P-labelled neomycine 
phosphotransferase- or glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific 
probes (upper and lower panels, respectively). The positions of 28 S and 18 S ribosomal RNA 
are indicated. (C) Effect of various antiviral agents on HEV RNA replication in HEV3 Rep/Neo 
cells. HEV RNA (solid circles) and cell viability (triangles) were determined by RT-qPCR and 
the Cell Proliferation Reagent WST-1 (Roche, Basel, Switzerland), respectively, after 48 h of 
treatment with increasing concentrations of the indicated antiviral agents. Results are 
expressed as % relative to the carrier-treated control. Each data point represents the mean ± 
SEM of at least 3 independent experiments performed in triplicate each. (D) HEV RNA in S10-
3 cells transfected with the full-length p6 clone. Non-transfected (nt) and cells transfected with 
full-length p6 (wt) or replication-defective control (GAD) RNA were treated for 48 h with carrier 
alone (-), 100 IU/ml interferon-α (IFN), 100 µM ribavirin (RBV), 10 µM nesbuvir (Nes) or 10 µM 
sofosbuvir (SOF). Results are expressed as % relative to the carrier-treated control. Each data 
point represents the mean ± SEM of at least 2 independent experiments performed in duplicate 
each. (E) ORF2 protein expression. Lysates from cells treated as in (D) were analyzed by 
immunoblot for the HEV ORF2 (capsid) protein and β-actin. The lower panel represents the 
mean ± SEM of two independent experiments. 
 
Figure 2. The combination of sofosbuvir and ribavirin results in an additive antiviral 
effect on HEV RNA replication. (A, C) Effect of the combination of various concentrations of 
sofosbuvir (SOF) and ribavirin (RBV) on HEV RNA replication in (A) HEV3 Rep/Neo cells and 
(C) HEV gt 3-infected human induced pluripotent stem cell-derived hepatocyte-like cells (iHep). 
HEV RNA levels were quantified by RT-qPCR after 48 h of treatment with increasing 
concentrations of SOF (0, 0.1, 1, 10 µM) and RBV (0, 1, 10, 100 µM). Results are expressed 
as % relative to the carrier-treated control. Each data point represents the mean ± SEM of 2 
independent experiments. (B, D) Synergy plot representing the % antiviral activity above or 
below the expected activity for the RBV-SOF combination based on the data depicted in panels 
A and C, respectively. 
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Supplementary Material 
 
Material and Methods 
 
Antiviral agents 
Interferon-α (IFN-α) was purchased from Roche Pharmaceuticals (Basel, Switzerland), 
ribavirin and lamivudine from Sigma-Aldrich (St. Louis, MO), sofosbuvir from Alsachim SAS 
(Illkirch-Graffenstaden, France) and nesbuvir from Selleck Chemicals (Houston, TX). Tenofovir 
was a kind gift of Gilead Sciences (Foster City ,CA). All compounds except IFN-α were 
dissolved in DMSO. 
 
Plasmids and cells 
Plasmids encoding the HEV genotype 3 Kernow-C1 p6 strain, the genotype 1 Sar55/S17/luc 
replicon and S10-3 cells were a kind gift from Suzanne U. Emerson, National Institutes of 
Health, Bethesda, MD [1, 2]. S10-3, Huh-7 and HepG2/C3A cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM; Life Technologies, Carlsbad, CA) supplemented with 10% 
fetal bovine serum (FBS; Life Technologies). HEV3 Rep/Neo cells were cultured in DMEM 
supplemented with 10% FBS and 500 µg/ml G418 (Life Technologies). 
The subgenomic HEV replicon construct harboring a neomycin phosphotransferase selection 
gene was derived from plasmid p6. Two-step PCR using primers HEVgt3-4487-fd (5'-
CCCGTGGTTCCGTGCCATTG-3') and HEV-Neo-rv (5'-
AATCCATCTTGTTCAATCATGGTGATCCCATGGGCGATG-3') as well as HEV-Neo-fd (5'-
CATCGCCCATGGGATCACCATGATTGAACAAGATGGATT-3') and Neo-rv (5'-
CGCAGAATAGCACCACGTGTTAGAAGAACTCGTCAAGAA-3') was performed on plasmids 
p6 and pcDNA3.1, respectively, followed by overlap extension PCR, digestion of the 
amplification product with AflII and PmlI, and cloning into plasmid p6, yielding plasmid p6/Neo. 
The full-length HEV p6 genome carrying a GAD mutation in the polymerase active site was 
prepared similarly. Two-step PCR using primers HEVgt3-4487-fd (see above) and HEVp6-
GAD-rv (5'-AGGACCACCGAATCAGCACCCTTAAAGGC-3') as well as HEVp6-GAD-fd (5'-
GCCTTTAAGGGTGCTGATTCGGTGGTCCT-3') and HEV-5897-rv (5'- 
GATGCCTCAGTAGCCATGAT-3') was performed on plasmid p6, followed by overlap 
extension PCR, digestion of the amplification product with AflII and PmlI, and cloning into 
plasmid p6, yielding plasmid p6/GAD. 
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Northern blot 
Total RNA was extracted from HEV3 Rep/Neo and parental S10-3 cells using the ReliaPrep 
RNA Cell Miniprep System (Promega, Madison, WI). Twenty µg of total cellular RNA each 
were separated by 1% denaturing agarose gel electrophoresis, followed by transfer onto a 
nitrocellulose membrane (Life Technologies) and Northern blot using a 32P-labelled neomycine 
phosphotransferase- or glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific 
probe. 
 
Measurement of antiviral activity in HEV replicon cells 
HEV3 Rep/Neo cells were seeded into 24-well plates at a density of 8 x 104 cells per well. 
Antiviral agents were added the next day. Fourty-eight h later, cells were washed with PBS 
and total RNA was extracted as above, followed by reverse transcription using the PrimeScript 
RT Reagent Kit (Takara, Shiga, Japan). HEV positive-strand RNA and GAPDH expression 
were quantified with specific primers (HEV3-4740fd 5'-CAGAGCCGCAATGCGGCAGC-3' and 
HEV3-4968rv 5'-ATCAACACAGACCTGCGCAAC-3' or GAPDH-fd 5'-
GAAGGTGAAGGTCGGAGTC-3' and GAPDH-rv 5'-GAAGATGGTGATGGGATTTC-3', 
respectively) using the SYBR Select Master Mix (Life Technologies) in a StepOne Real-Time 
PCR cycler (Life Technologies). GraphPad Prism6 software was used to fit response curves 
with nonlinear regression analysis and to calculate IC50 values. 
Transient antiviral assays using the gt 3 p6/luc and gt1 Sar55/S17/luc replicons, combination 
studies with p6/luc and assessment of cell viability through the MTS/PMS method were 
performed as described previously [3]. 
Data from combination studies were analyzed with the MacSynergy II template [4]. 
 
Viral RNA preparation and transfection 
HEV RNA was in vitro transcribed from MluI-linearized plasmids p6/Neo, p6 or p6/GAD by the 
use of the mMESSAGE mMACHINE Kit (Life Technologies). Two-hundred ng of in vitro 
transcribed viral RNA was transfected into 105 S10-3 cells per well of a 12-well cell culture 
plate using the TransIT-mRNA transfection kit (Mirus Bio LLC, Madison, WI). Cells transfected 
with the subgenomic replicon construct were subjected to selection with 500 µg/ml G418 (Life 
Technologies) 3 d post-transfection. Cells transfected with the full-length HEV RNA were 
washed 4 d later and antiviral agents added for 48 h prior to cell lysis. RNA and protein levels 
were analyzed by RT-qPCR and immunoblot, respectively. 
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Generation of human induced pluripotent stem cell-derived hepatocyte-like cells 
Human induced pluripotent stem cells were differentiated into hepatocyte-like cells as 
described previously [5], with minor modifications. In brief, the base defined medium (DM) 
consisted of RPMI 1640, 1% B27 serum-free supplement, and 0.5% non-essential amino acids 
(all from Life Technologies). To induce endoderm differentiation, an iPS.C3A cell subclone [5, 
6] was harvested with gentle cell dissociation reagent (Stemcell Technologies, Vancouver, 
Canada) and plated into Matrigel-coated culture dishes (Corning, New York, NY) in mTeSR1 
medium (Stemcell Technologies). The next day, culture medium was changed to medium A 
(DM/activin-A/basic fibroblast growth factor [bFGF]/Wnt-3A) for 24 h, followed by 72 h of 
culture in medium B (DM/activin-A/bFGF). To induce hepatic differentiation, definitive 
endoderm cells were re-seeded and cultured in the presence of medium C (DM/bone 
morphogenic protein 4 [BMP-4]/bFGF) for five days and then in the presence of medium D 
(DM/epidermal growth factor [EGF]/hepatocyte growth factor [HGF]) for five more days. Finally, 
cells were matured in Hepatocyte Culture Medium (Lonza, Basel, Switzerland) supplemented 
with oncostatin-M for five to seven days before being used for infection. 
Activin-A, Wnt-3A and oncostatin-M were purchased from R&D Systems (Minneapolis, MN), 
bFGF was from Life Technologies, and BMP-4, EGF and HGF were purchased from Peprotech 
(Rocky Hill, NJ). 
 
HEV infection of iHeps 
Full-length HEV genotype 3 Kernow-C1 p6 strain RNA was prepared and transfected into S10-
3 cells as described above. Six days post-transfection S10-3 cells were frozen and thawed 
three times to release infectious HEV, followed by centrifugation for 2 min at 10,000 x g. to 
remove cell debris. iHeps were infected using the HEV-containing recovered S10-3 cell lysate 
for 12-16 h, followed by removal of the inoculum by thorough but gentle washes with culture 
medium (Wu X, Dao Thi VL et al., manuscript in preparation). Antiviral agents were added to 
the culture medium 3 d post-infection. Cells were harvested for RT-qPCR analysis at 3 d post-
treatment with antiviral agents. 
 
Immunoblot 
Cell lysates were separated by 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis, followed by transfer onto polyvinylidene fluoride membrane (Merck-Millipore), 
as described previously [7]. HEV ORF2 protein was detected using monoclonal antibody 1E6 
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(Merck-Millipore) and β-actin using monoclonal antibody AC-74 (Sigma-Aldrich). ORF2 band 
intensities were quantified using ImageJ software. 
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Supplementary Figure 1. Sofosbuvir inhibits replication of a transient HEV gt 3 reporter 
replicon. Effect of sofosbuvir (SOF) in a transient HEV RNA replication assay. HEV RNA 
replication in Huh-7 cells transfected with genotype 3 p6/luc and genotype 1 Sar55/S17/luc 
replicon RNA was determined by Gaussia luciferase-derived luminescence and cell viability 
was assessed using the MTS/PMS method as described previously [3]. Each data point 
represents the mean ± SEM of 3 independent experiments. 
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Supplementary Figure 2. Lamivudine and tenofovir do not inhibit HEV replication. (A) 
Effect of lamivudine and tenofovir on HEV RNA replication in HEV3 Rep/Neo cells. HEV RNA 
(solid circles) and cell viability (triangles) were determined by RT-qPCR and the Cell 
Proliferation Reagent WST-1 (Roche, Basel, Switzerland), respectively, after 48 h of treatment 
with increasing concentrations of the indicated antiviral agents. Results are expressed as % 
relative to the carrier-treated control. Each data point represents the mean ± SEM of 2 
independent experiments performed in triplicate each. (B) Effect of lamivudine and tenofovir 
in a transient HEV RNA replication assay. HEV RNA replication in Huh-7 cells transfected with 
genotype 3 p6/luc and genotype 1 Sar55/S17/luc replicon RNA was determined by Gaussia 
luciferase-derived luminescence and cell viability was assessed using the MTS/PMS method 
as described previously [3]. Each data point represents the mean ± SEM of 3 independent 
experiments. 
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Supplementary Figure 3. The combination of sofosbuvir and ribavirin results in an 
additive antiviral effect on HEV RNA replication in a transient replication assay. Synergy 
plot representing the % antiviral activity above or below the expected activity for the 
combination of sofosbuvir (SOF) and ribavirin (RBV) based on the data depicted in 
Supplementary Figure 1. 
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